Transforming growth factor-beta 3 alters intestinal smooth muscle function: implications for gastroschisis-related...

Area of Science:

• Gastroenterology
• Developmental Biology
• Molecular Biology

Background:

• Gastroschisis (GS) is a congenital defect causing intestinal dysfunction (GRID).
• Transforming growth factor-beta (TGF-β) is a pro-inflammatory cytokine implicated in organ dysfunction.
• TGF-β3's role in GS-related intestinal smooth muscle dysfunction requires investigation.

Purpose of the Study:

• To evaluate the effects of TGF-β3 on intestinal smooth muscle function.
• To assess TGF-β3's impact on contractile gene expression in the intestine.

Main Methods:

• Analysis of human intestinal tissue for TGF-β isoforms and smooth muscle markers using immunohistochemistry and RT-PCR.
• Measurement of intestinal motility in neonatal rats exposed to TGF-β3.
• Assessment of human intestinal smooth muscle cell (hiSMC) contractility and gene expression following TGF-β3 incubation.

Main Results:

• Increased TGF-β3 and micro-RNA 143 & 145 levels were observed in GS infant intestinal smooth muscle.
• TGF-β3 exposure led to dose-dependent decreases in rat intestinal transit.
• TGF-β3 significantly enhanced hiSMC contraction and contractile gene/micro-RNA expression.

Conclusions:

• TGF-β3 contributes to intestinal dysfunction at organ, cellular, and molecular levels.
• A hyper-contractile smooth muscle response mediated by TGF-β3 may underlie persistent GRID.
• Targeting TGF-β3 pathways could offer therapeutic potential for GRID.